Eterna acquires Exacis’ allogeneic immuno-oncology platform
Drug Discovery World
MAY 5, 2023
The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs). “We We are excited to bring this powerful platform into Eterna.
Let's personalize your content